Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment by Betson, Martha et al.
Detection of persistent Plasmodium spp. infections in
Ugandan children after artemether-lumefantrine treatment
MARTHA BETSON1, JOSÉ C. SOUSA-FIGUEIREDO2, AARON ATUHAIRE3,
MOSES ARINAITWE3, MOSES ADRIKO3, GERALD MWESIGWA3, JUMA NABONGE4,
NARCIS B. KABATEREINE3, COLIN J. SUTHERLAND2 and J. RUSSELL STOTHARD5*
1Department of Production and Population Health, Royal Veterinary College, Hatﬁeld, Hertfordshire, UK
2Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
3Vector Control Division,Ministry of Health, Kampala, Uganda
4Vector Control Division,Mayuge District, Uganda
5Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK
(Received 19 December 2013; revised 14 February 2014; accepted 23 February 2014; first published online 16 May 2014)
SUMMARY
During a longitudinal study investigating the dynamics of malaria in Ugandan lakeshore communities, a consistently high
malaria prevalence was observed in young children despite regular treatment. To explore the short-term performance of
artemether-lumefantrine (AL), a pilot investigation into parasite carriage after treatment(s) was conducted in Bukoba
village. A total of 163 children (aged 2–7 years) with a positive blood ﬁlm and rapid antigen test were treated with AL; only
8·7% of these had elevated axillary temperatures. On day 7 and then on day 17, 40 children (26·3%) and 33 (22·3%) were
positive by microscopy, respectively. Real-time PCR analysis demonstrated that multi-species Plasmodium infections
were common at baseline, with 41·1% of children positive for Plasmodium falciparum/Plasmodium malariae, 9·2% for
P. falciparum/ Plasmodium ovale spp. and 8·0% for all three species. Moreover, on day 17, 39·9% of children infected with
falciparum malaria at baseline were again positive for the same species, and 9·2% of those infected with P. malariae at
baseline were positive for P. malariae. Here, chronic multi-species malaria infections persisted in children after AL
treatment(s). Better point-of-care diagnostics for non-falciparum infections are needed, as well as further investigation of
AL performance in asymptomatic individuals.
Key words: artemisinin combination therapy, malaria, rapid diagnostic test, Uganda, Plasmodium falciparum, Plasmodium
malariae, Plasmodium ovale.
INTRODUCTION
Malaria remains a substantive public health problem
inUganda, particularly in young children.Challenges
to eﬀective malaria control in this country include an
extremely high transmission intensity with entomo-
logical inoculation rates greater than 100 per year in
many areas, a weak health system with a fragile
supply chain for front-line antimalarial treatments,
inadequate case management with poor diagnostic
tools in rural health centres and ineﬀective monitor-
ing and evaluation of control interventions (Yeka
et al. 2012). To reduce the burden of clinical disease,
Uganda adopted aﬁxeddose artemisinin combination
therapy (ACT) of artemether-lumefantrine (AL), as
its ﬁrst-line treatment for uncomplicated falciparum
malaria in 2006 (Batwala et al. 2010) and a number
of trials indicate that AL is highly eﬃcacious and
safe in this country (Bukirwa et al. 2006; Dorsey et al.
2007;Kamya et al. 2007; Yeka et al. 2008; Achan et al.
2009; Arinaitwe et al. 2009; Bassat et al. 2009;
The Four Artemisinin-Based Combinations
(4ABC) Study Group, 2011). Despite concerns
about non-compliance i.e. non-completion of the
3-day course of antimalarial therapy, high levels of
adherence to home-based AL treatment and very
similar high cure rates were found in a trial comparing
unsupervised and supervised treatment (Fogg et al.
2004; Piola et al. 2005).
Since ACTs are relatively expensive and to
ensure correct clinical management of febrile illness,
the World Health Organization (WHO) promotes
a ‘test-and-treat’ strategy for malaria involving
parasitological diagnosis rather than presumptive
treatment based on clinical indicators (WHO,
2010a). The gold standard for malaria diagnosis
remains light microscopy, however, this can be
diﬃcult to implement in rural clinical settings due
to a shortage of equipment and trained staﬀ. Many
African countries, including Uganda, are now intro-
ducing rapid diagnostic tests (RDTs) for malaria
diagnosis in local health centres and for community-
based malaria management (Drakeley and Reyburn,
2009). However, as there are a plethora of RDTs for
detection of falciparum and vivax malaria produced
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by a range of manufacturers, which vary in format
and diagnostic performance, adoption of the ‘best’
test can be problematic (WHO, 2012). Common
antigen targets for RDTs, histidine-rich protein 2
(HRP2; Plasmodium falciparum-speciﬁc) and lactate
dehydrogenase (LDH; pan-Plasmodium or species-
speciﬁc), display marked diﬀerences in their sensi-
tivity, stability and dynamics of clearance from the
blood after antimalarial treatment (Aydin-Schmidt
et al. 2013; Nyunt et al. 2013).
Although P. falciparum remains the major cause
of morbidity and mortality in sub-Saharan Africa,
non-falciparum infections, such as Plasmodium
vivax, Plasmodium malariae and Plasmodium ovale
spp., are also present in humans and their clinical
signiﬁcance should not be overlooked (Collins
and Jeﬀery, 2005, 2007; Mueller et al. 2007, 2009).
Plasmodium malariae and P. ovale spp. infections, in
particular, are often challenging to diagnose by
microscopy due to low parasitaemias and diﬃculties
in distinguishing from P. falciparum, particularly in
cases of mixed infection (Mueller et al. 2007). In fact,
PCR-based methods have revealed that P. malariae
and P. ovale spp. are more prevalent in sub-Saharan
Africa than previously thought based on microscopic
diagnosis (Mueller et al. 2007, 2009; Bruce et al.
2008; Oguike et al. 2011; Proietti et al. 2011).
Unfortunately these methodologies are not readily
deployed in remote resource-poor settings and the
RDTs tested to date generally show poor diagnostic
performance in detection of P. malariae and P. ovale
spp. infections in individuals (Maltha et al. 2013a,b).
In non-immune travellers, the sensitivities of RDTs
range from 21·4 to 85·7% for P. malariae detection
and from 5·5 to 86·7% for P. ovale (Houzé et al. 2011;
Maltha et al. 2013b). There has been very little
reported on the diagnostic performance of RDTs for
these malaria species in endemic settings, likely due
to their low prevalence (as detected by microscopy)
and the fact that they often exist as mixed infections
with other malaria species.
In line with national treatment guidelines and to
develop a strategy for treatment of schistosomiasis in
under 5 s, a closed-cohort longitudinal study was
initiated in 2009 investigating schistosomiasis and
malaria in mothers and young children living in six
communities in Uganda (the Schistosomiasis in
Mothers and Infants or SIMI project) (Betson et al.
2010). Over the course of this project AL was pro-
vided to all RDT-proven malaria cases at the time of
the survey(s). Although on-site treatment decisions
were based on RDT results, the vast majority of
RDT-positives were subsequently shown to be
parasitaemic by microscopy and PCR (Sousa-
Figueiredo et al. 2010). In addition, we observed
a substantial number of cases of co-infection of
P. falciparum with P. malariae and/or P. ovale spp.
(Oguike et al. 2011). More importantly, we noticed
that many children in these areas of intense malaria
transmission required repeated AL treatment, up to
ﬁve times within 18 months. At the end of this
longitudinal study, we considered that a pilot study
was needed to gather evidence on the eﬀectiveness
of AL against P. falciparum and non-falciparum
malaria in this setting. Herewe report on a short-term
observational follow-up study of children using
microscopy, RDTs and molecular detection of
parasites.
MATERIALS AND METHODS
Study area, participants and sampling
The SIMI (Schistosomiasis in Mothers and Infants)
community-based longitudinal study was conducted
in six villages on the shores of Lake Albert and Lake
Victoria in Uganda, commencing in May 2009
(Betson et al. 2010; Stothard et al. 2011, 2013). A
total of 1856mothers and children under 6 years were
recruited at baseline and followed-up at 3, 6, 12 and
18 months (Lake Victoria only) later. During
the SIMI study, malaria diagnosis was carried out
using a combination of Paracheck-Pf® RDTs (Orchid
Biomedical Systems, Goa, India) or First Response
RDTs (HRP-2 based; Premier Medical Corporation,
NJ, USA), OptiMAL RDTs (Diamed GmBH,
Switzerland) and microscopy on Giemsa-stained
blood ﬁlms as described (Sousa-Figueiredo et al.
2010), as well as real-time PCR (see below). Preva-
lence levels of malaria infection in all mothers and
children recruited to the SIMI study are summarized
in Table 1 with stratiﬁcation by lake and survey
timepoint.
Bukoba village, Mayuge District, showed the
highest prevalence of falciparum and non-falciparum
malaria in young children (see Table 2) and so was
chosen as the site for the AL follow-up study, which
was conducted in November and December 2010
(Betson et al. 2010; Stothard et al. 2011). A group of
children from Bukoba village (N = 163) within the
SIMI cohort (N= 188) were recruited to the study on
the basis of a positive First Response RDT result and
microscopy-conﬁrmed malaria. Children were sub-
sequently followed up 7 and 17 days after day 0 (day
of initiation of treatment). Due to ﬁnancial and
logistical constraints, only individuals who were
RDT-positive on day 17 (see below), who had been
given oral quinine sulphate as an alternative exit
treatment, were followed up on day 24. A blood
smear archive was made on days 0, 7 and 17, and
conﬁrmatory microscopy was carried out 2 or 3 days
after each sample was taken (Sousa-Figueiredo et al.
2010). Blood spots were collected onto Whatman®
3MM ﬁlter paper at all timepoints for molecular
analyses (see below). In addition, haemoglobin (Hb)
levels were recorded for each child using a HemoCue
spectrometer (HemoCue AB, Angelholm, Sweden)
on days 0, 7 and 17.
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Table 1. Prevalence of malaria at diﬀerent survey time points in mothers and children participating in the SIMI study at Lake Albert and Lake Victoria
Lake Survey
Mothers Children Both
Slide % (95% CI) [n/N ] RDT % (95% CI) [n/N ] Slide % (95% CI) [n/N ] RDT % (95% CI) [n/N ] Slide % (95% CI) [n/N ] RDT % (95% CI) [n/N ]
Albert Baseline 22·0 (17·6–26·8) [72/328] 17·6 (13·5–22·2) [56/319] 60·5 (56·4–64·6) [339/560] 64·7 (60·6–68·7) [356/550] 46·3 (43·0–49·6) [411/888] 47·4 (44·0–50·8) [412/869]
6 months 24·5 (19·2–30·4) [60/245] 24·3 (19·0–30·2) [59/243] 75·2 (70·8–79·3) [310/412] 76·0 (71·6–80·1) [314/413] 56·3 (52·4–60·1) [370/657] 56·9 (53·0–60·7) [373/656]
12 months 17·7 (13·0–23·3) [40/226] 14·0 (9·9–19·0) [34/243] 66·0 (60·9–70·9) [241/365] 68·0 (63·2–72·5) [274/403] 47·5 (43·5–51·7) [281/591] 47·7 (43·8–51·6) [308/646]
Victoria Baseline 26·5 (21·8–31·7) [87/328] 26·7 (22·0–31·8) [88/330] 82·7 (79·5–85·5) [520/629] 86·5 (83·6–89·1) [551/637] 63·4 (60·3–66·5) [607/957] 66·1 (63·0–69·1) [639/967]
6 months 23·7 (18·4–29·5) [57/241] 24·9 (19·6–30·9) [60/241] 72·4 (68·2–76·4) [352/486] 72·2 (68·0–76·2) [351/486] 56·3 (52·6–59·9) [409/727] 56·5 (52·8–60·2) [411/727]
12 months 30·9 (24·9–37·5) [68/220] 28·9 (23·1–35·3) [65/225] 70·2 (65·4–74·7) [278/396] 82·7 (78·8–86·2) [359/434] 56·2 (52·1–60·1) [346/616] 64·3 (60·5–68·0) [424/659]
18 months 29·8 (23·7–36·5) [62/208] 35·5 (29·1–86·2) [77/217] 82·6 (78·6–86·2) [338/409] 88·9 (85·5–91·7) [384/432] 64·8 (60·9–68·6) [400/617] 71·0 (67·4–74·5) [461/649]
Table 2. Prevalence of diﬀerent malaria species in mothers and children at baseline
Lake Village
Mothers Children
N
P. falciparum %
(95% CI)
P. malariae %
(95% CI)
P. ovale spp. %
(95% CI) N
P. falciparum %
(95% CI)
P. malariae %
(95% CI)
P. ovale spp. %
(95% CI)
Albert Bugoigo 130 41·5 (33·40–50·5) 1·5 (0·2–5·4) 0 (0–2·8) 216 65·7 (59·0–72·0) 1·4 (0·3–4·0) 1·4 (0·3–4·0)
Walukuba 120 26·1a (18·4–34·9) 1·7 (0·2–5·9) 0 (0–3·0) 194 61·7b (54·4–68·5) 5·2 (2·5–9·3) 0·5 (0·01–2·8)
Piida 82 36·6 (26·2–48·0) 0 (0–4·4) 0 (0–4·4) 161 67·7 (59·9–74·8) 6·2 (3·2–10·6) 0 (0–4·4)
Victoria Bugoto 134 42·5 (34·0–51·4) 1·5 (0·2–5·3) 0 (0–2·7) 258 79·51 (74·0–84·2) 8·9 (5·7–13·1) 1·6 (0·4–3·9)
Bukoba 126 47·6 (38·7–56·7) 2·4 (0·5–6·8) 0·8 (0·02–4·3) 248 87·5 (82·7–91·3) 14·5 (10·4–19·5) 8·5 (5·3–12·7)
Lwanika 70 24·2 (14·8–36·0) 0 (0–5·1) 0 (0–5·1) 133 79·7 (71·9–86·2) 3·8 (1·2–8·6) 3·8 (1·2–8·6)
a N = 119.
b N = 193.
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Treatment
To allow rapid treatment in this village setting,
treatment decisions were based on the results of
RDTs (Fig. 1). At baseline the HRP2-based First
Response Test was used, which demonstrates very
high sensitivity in detection of P. falciparum infec-
tions (WHO, 2008). On Days 7 and 17, treatment
decisions were based on the results of the OptiMAL
RDT (Diamed GmBH, Switzerland), an LDH-
based test, because the LDH antigen clears much
more rapidly from the blood after treatment than
HRP2, with average clearance times ranging from 3·7
to 7 days for LDH and 20 to 28 days for HRP2
(Aydin-Schmidt et al. 2013; Nyunt et al. 2013). On
day 0 all participants were treated with AL (20mg
artemether/120mg lumefantrine; LONART, Bliss
Gvs Pharma Ltd., India) (WHO, 2010a). Two
tablets of LONART were tested for quality and
shown to contain exactly the expected amount of
artemether and lumefantrine (H. Kaur, personal
communication). A nurse administered the ﬁrst AL
dose, which was accompanied by fatty food, a
mandazi (local doughnut). Subsequent AL doses
were administered at home by the child’s mother
following the nurse’s instructions. Children who
were OptiMAL-positive on day 7 were treated a
second time with AL. On day 17, OptiMAL-positive
children were treated with oral quinine sulphate,
the second-line antimalarial drug in Uganda
(WHO, 2010a). At baseline children were tested
for Schistosomiasis mansoni and soil-transmitted
helminth infections by microscopic detection of
eggs in stool as described (Katz et al. 1972; Betson
et al. 2010). On day 0 all children were treated with
praziquantel (40mg kg−1) and albendazole (400mg)
according to WHO guidelines (WHO, 2006).
Molecular analysis
To bolster microscopy ﬁndings and to detect non-
falciparum infections, genomic DNA was extracted
from dried blood spots using the chelex method
(Dlamini et al. 2010) and real-time PCR diagnosis of
Plasmodium infections was performed as described
(Shokoples et al. 2009). A Ct value of 40 was used
as a cut-oﬀ to diﬀerentiate between positives and
negatives for each malaria species. To distinguish
between recrudescent and new falciparum infections,
Fig. 1. Schematic representation of the study protocol, showing tests employed at each time point, numbers of
participants and treatment protocol. On days 7 and 17, treatment decisions were based on the results of OptiMAL tests
(LDH) to allow rapid treatment in the ﬁeld.
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genotyping of merozoite surface proteins (msp1 and
msp2) and glutamate-rich protein (glurp) was carried
out according to published methods (Felger and
Snounou, 2008). All PCR products were subject to
polyacrylamide gel electrophoresis (10%) and frag-
ment sizing was carried out using a GelDoc system
and Image Lab gel analysis software (Biorad,
Hercules, CA, USA). Infections were classiﬁed as
either recrudescent or new infections on the basis of
fragment sizes (WHO, 2007).
Mapping of households
To build a comprehensive picture of spatial epidemi-
ology of infections in the community, GPS coordi-
nates of the households in the SIMI cohort have been
collected (Stothard et al. 2011). The households
of children in this study and their infection status
by microscopy on days 7 and 17 were annotated
using ArcView 9.3 (ESRI, CA, USA) GIS (Fig. 4).
To determine whether there was any clustering of
malaria infections on day 7 or day 17, the data were
analysed using a Bernoulli model in SatScan v9.2.
Statistical analysis
Epidemiological data were analysed using Stata v9.2
(StatCorp, TX, USA) and R v2.10.1 (The R
Foundation for Statistical Computing, Vienna,
Austria). Anaemia was categorized based on haemo-
globin levels as follows: mild 10–11 g dL−1, mode-
rate 7–10 g dL−1 and severe <7 g dL−1 (WHO, 2001).
To determine how the diﬀerent malaria species
responded to AL treatment, the percentage of
children infected with each species on days 7 and 17
(as assessed by real-time PCR) was calculated using
the number of children infected with that species at
baseline as the denominator (Fig. 3).
Ethical approval
Ethical approval was provided by The London
School of Hygiene and Tropical Medicine and the
Ugandan National Council of Science and
Fig. 2. Malaria infection prevalence on days 0, 7 and 17 as assessed by microscopy, real-time PCR or either method.
Error bars represent 95% conﬁdence intervals.
Fig. 3. Percentage of the children positive for each
malaria species at baseline (as assessed by real-time PCR)
who were also positive on days 7 and 17. Error bars
represent 95% conﬁdence intervals. N= number of
children in the denominator.
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Technology. Informed consent was given bymothers
on behalf of their children and documented in writing
or by thumbprint (in cases of illiteracy).
RESULTS
Table 3 details the characteristics of the AL follow-
up study participants. The children ranged in age
from 2–7 years and 48·5% were female. Only 8·7% of
children had low-grade fever at baseline but 28·8%
had moderate or severe anaemia. Although the
prevalence of S. mansoni infection was very low,
9·0% of children had egg-patent hookworm infec-
tions.
Malaria infection status at diﬀerent time points is
summarized in Table 4 and Fig. 2. On day 0, all 163
children were positive by microscopy with a geo-
metric mean parasitaemia of 1640·4 parasites μL−1
blood. On day 7, 40 children (26·3%) remained
malaria positive by microscopy and on day 17, 33
children (21·3%) had microscopically detectable
malaria infections. After genotyping using msp1,
msp2 and glurp loci, 33 out of 40 and 17 out of
33 children were shown to have recrudescent
P. falciparum infections on days 7 and 17, respect-
ively. By real-time PCR 96·9% of children were
positive for P. falciparum on day 0 and multi-species
Plasmodium infections were common, with 41·1%
positive for P. falciparum/P. malariae, 9·2% positive
for P. falciparum/P. ovale spp. and 8·0% for all
three species (Table 4; Fig. 2). Although there was a
reduction in anaemia prevalence and severity over the
course of the study, 22 children were anaemic on day
17 (Table 4).
Table 5 summarizes malaria infection in relation to
number of antimalarial treatments. Eleven of the 28
children who had received two consecutive treat-
ments with AL (on days 0 and 7) were positive by
Fig. 4. From left to right: map of positive (red) and negative (green) children according to microscopy at day 7; map of
positive (red) and negative (green) children according to microscopy at day 17.
Table 3. Characteristics of AL follow-up study
participants (N= 163) and health indicators
Characteristic Value
Age mean (range)
Years 4 (2–7)
Gender n (%)
Female 79 (48·5)
Clinical n (%)
Axillary temperature >37·5 °C 14 (8·7)
Haemoglobin <10 g dL−1 47 (28·8)
Hepatomegalya 25 (15·5)b
Splenomegalya 68 (42·5)c
S. mansoni infectiond 3 (1·9)e
Hookworm infectiond 14 (9·0)e
a As recorded by physical palpation according to clinical
guidelines.
b N= 160.
c N= 161.
d Egg patent upon faecal examination.
e N= 155.
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Table 4. Parasitaemia and prevalence of malaria infection and anaemia at days 0, 7 and 17
Day 0 N= 163 (95% CI)a [n] Day 7 N= 152 (95% CI) [n] Day 17 N= 148 (95% CI) [n]
Parasitaemia (parasites μL−1) Geometric mean 1640·4 (1298·1–2073·0) 578·7 (351·0–954·2) 457·7 (185·2–1131·1)
Range 20–90640 31·4–10360 5·4–101080
Prevalence by microscopy (%) Any parasitaemia 100 (97·8–100) [163] 26·3 (19·5–34·1) [40] 22·3 (15·9–29·9) [33]
1–500 (parasites μL−1) 18·4 (12·8–25·2) [30] 9·9 (5·6–15·8) [15] 10·1 (5·8–16·2) [15]
500–2000 (parasites μL−1) 37·4 (30·0–45·3) [61] 9·9 (5·6–15·8) [15] 8·1 (4·3–13·7) [12]
2000–10000 (parasites μL−1) 33·1 (26·0–40·9) [ 54] 5·9 (2·7–10·9) [9] 0·7 (0·01–3·7) [1]
>10000 (parasites μL−1) 11·1 (6·7–16·9) [18] 0·7 (0·02–3·6) [1] 3·4 (1·1–7·7) [5]
PCR-corrected (P. falciparum only) – 21·9 (15·5–29·3)b [33] 11·7 (7·0–18·1)c [17]
Prevalence by real-time PCR (%) P. falciparum 96·9 (93·0–99·0) [158] 50·0 (41·8–58·2) [76] 39·2 (31·3–47·5) [58]
P. malariae 49·7 (41·8–57·6) [81] 12·5 (7·7–18·8) [19] 6·1 (2·8–11·2) [9]
P. ovale spp. 17·8 (12·3–24·5) [29] 5·3 (2·3–10·1) [8] 2·0 (0·4–5·8) [3]
Prevalence of mixed infections
by real-time PCR (%)
P. falciparum/P. malariae 41·1 (33·5–49·1) [67] 10·5 (6·1–16·5) [16] 5·4 (2·4–10·4) [8]
P. falciparum/P. ovale spp. 9·2 (5·2–14·7) [15] 3·3 (1·1–7·5) [5] 1·4 (0·2–4·8) [2]
P. falciparum/P. malariae/P. ovale spp. 8·0 (4·3–13·3) [13] 1·3 (0·2–4·7) [2] 0·7 (0·01–3·7) [1]
Prevalence of anaemia (%) Any anaemia 56·4 (48·5–64·2) [92] 45·4 (37·3–53·7) [69] 14·9 (9·6–21·6) [22]
Mild 27·6 (20·1–35·1) [45] 27·6 (20·1–35·5) [42] 10·8 (6·3–17·0) [16]
Moderate 27·6 (20·1–35·1) [45] 17·8 (12·0–24·8) [27] 4·1 (1·5–8·6) [6]
Severe 1·2 (0·1–4·4) [2] 0 0
a 95% CI = 95% conﬁdence interval.
b N = 151.
c N = 145.
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microscopy on Day 17. At this timepoint, 16 children
were P. falciparum positive by real-time PCR, six
children were infected with P. malariae and two with
P. ovale spp. On day 24, after two or three consecutive
antimalarial treatments, 10 children were infected
with P. falciparum and two were also infected with
P. malariae (Table 5). When the performance of AL
on diﬀerent Plasmodium species was investigated,
39·9% of the children infected with falciparum
malaria at baseline were still P. falciparum positive
on Day 17, whereas 9·2% of those who were
P. malariae positive at baseline showed P. malariae
infection on Day 17 (Fig. 3).
To determine whether there were diﬀering risks
of infection after treatment for children living in
diﬀerent parts of the village, their households
and infection status on days 7 and 17 were mapped
(Fig. 4). Spatial analysis using SatScan suggested six
possible clusters of positive children on both day 7
and day 17. However, the statistical support for each
cluster was low with P values greater than 0·1 in each
case (data not shown). Thus strong evidence for
clustering of malaria infections after AL treatment
was not found, although this may reﬂect a lack of
power due to the small numbers of infected indivi-
duals on days 7 and 17.
DISCUSSION
In light of the challenges in diagnosis of falciparum
and non-falciparum malaria and the chronically high
prevalence of infections in Bukoba village, Uganda,
we document the short-term eﬀect of AL treatment
on multiple malaria species in a cohort of young
children living in this area. The studywas designed to
gain insights into treatment responses when AL was
distributed to parasitaemic children in a community-
based setting (unsupervised treatment), rather than
as a carefully controlled standard eﬃcacy trial. It is
outside the remit of this paper to explore how well
the results of standard eﬃcacy trials predict the
eﬀectiveness of home-based management strategies
in the same population. However, we found by
microscopy that 26·3% of treated children (21·9%
recrudescent by PCR genotyping) showed P. falci-
parum parasitaemia 7 days after treatment and that
22·3% (11·7% recrudescent) had parasites in their
blood after 17 days, despite the fact that 33% of these
positive children had already been retreated with AL
at day 7. A substantial number of additional recurrent
infections were identiﬁed by real-time PCR, includ-
ingP.malariae andP. ovale spp. infections. Although
none of these infections could be considered ‘com-
plicated’ clinical malaria, their signiﬁcance needs to
be better quantiﬁed.
Our results are surprising given that clinical trials
of AL in Uganda using microscopic diagnosis found
that parasite clearance was rapid (very few detectable
infections by day 3), there was negligible risk of
parasitaemia before day 21 and that risks of treatment
failure by day 28 ranged from 1–9% (Bukirwa et al.
2006; Dorsey et al. 2007; Kamya et al. 2007; Yeka
et al. 2008; Achan et al. 2009; Arinaitwe et al. 2009;
The Four Artemisinin-Based Combinations (4ABC)
Study Group, 2011). In contrast, a trial in Ghana
found day 28 failure rates of 14% (Owusu-Agyei et al.
2008) and a longitudinal community-based study in
Papua New Guinea found a PCR-corrected para-
sitological treatment failure rate of 19·8% for AL
(Schoepﬂin et al. 2011). Although artemisinin-
tolerant falciparum has been reported in East Asia
(Noedl et al. 2008; Dondorp et al. 2009), there has
been little evidence to date of reduced eﬃcacy of AL
in Africa in standard clinical trials. Borrmann et al.
reported a small decline in parasitological response
rates to ACTs (including AL) in coastal Kenya
(Borrmann et al. 2011). However, it is unclear
whether this change reﬂected increased tolerance of
the parasite to ACTs or reductions in clinical
immunity due to decreased malaria transmission. In
a number of African countries there appears to be
selection for 86N, 184F and 1246D alleles in the
Table 5. Summary of percentages of children who were malaria positive by PCR on days 17 and 24 after
one or two antimalarial treatments
Treatment(s)
Day 17 Day 24a
N % N %
Microscopy 1 AL 120 18·3 NS NS
2 AL 28 39·3 NS NS
Real-time PCR P. falciparum 1 AL 120 35·0 7 57·1
2 AL 28 57·1 7 85·7
P. malariae 1 AL 120 2·5 7 0
2 AL 28 21·4 7 28·6
P. ovale spp. 1 AL 120 0·8 7 0
2 AL 28 7·1 7 0
a All children who were followed up on day 24 had been treated with oral quinine on day 17.
1 AL= one AL treatment, 2 AL= two AL treatments; N= total number of individuals; NS = no slides.
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product of the P. falciparum multidrug-resistant
1 gene (pfmdr1) in recurrent infections soon after
AL treatment (Humphreys et al. 2007; Baliraine
and Rosenthal, 2011; Gadalla et al. 2011). These
polymorphisms as well as pfmdr1 ampliﬁcation
have been associated with decreased sensitivity of
P. falciparum in vitro to AL (Price et al. 2006). Thus,
there is potential for tolerance to AL to develop in
Africa.
This study was based on assessment of parasit-
aemia rather than clinical illness and most children
had asymptomatic infections on day 0. The 21-day
eﬃcacy of the ACT dihydroartemisinin piperiquine
(DP) for treatment of P. falciparum in parasitaemic
but asymptomatic Ghanaian schoolchildren was 91%
and it was suggested that chronic asymptomatic
infections may not respond as well to antimalarial
treatment as symptomatic infections because the
parasites do not stimulate immune responses which
can assist in parasite clearance (Dinko et al. 2013).
In our study the performance was much lower, but
there was no signiﬁcant diﬀerence in the treatment
responses of children with higher parasitaemia
(>2000 parasites μL−1) and those with lower para-
sitaemia (data not shown). Similar responses to AL
were also observed when children with fever or
moderate/severe anaemia on day 0 were compared
with those with no fever or anaemia. However, the
number of symptomatic individuals in our studymay
be too small to detect subtle diﬀerences in responses
to AL treatment between symptomatic and asympto-
matic individuals.
There has been little work assessing the dynamics
of parasite clearance after AL treatment using PCR,
although a median clearance time of 2 days has been
reported (Aydin-Schmidt et al. 2013). However,
additional submicroscopic infections have been
detected in children during post-treatment follow-
up using PCR (Gadalla et al. 2011; Aydin-Schmidt
et al. 2013; Beshir et al. 2013; Dinko et al. 2013), as
we report here. The importance of such sub-patent
malaria infections was recently demonstrated by
Beshir et al. in Kenya, who showed that residual
sub-microscopic parasitaemia on day 3 after com-
mencement of AL or DP treatment was associated
with longer gametocyte carriage, increased trans-
mission to mosquitoes and recurrence of micro-
scopically detectable malaria infections on day 24
or day 48 (Beshir et al. 2013). The incorporation of
PCR-based malaria diagnosis into the standard
protocols of ACT eﬃcacy studies will be important
to determine the extent of submicroscopic carriage of
malaria parasites after treatment.
The vast majority of P. malariae and P. ovale
infections detected by real-time PCR at baseline
were mixed infections with P. falciparum, which
were diﬃcult to detect on thick ﬁlms despite cross-
checking. Plasmodium malariae was not fully sensi-
tive to AL in this study as around 9% of infected
individuals were still positive on day 17, and two
children were P. malariae positive at day 24 after
three antimalarial treatments. The fact that 50% of
study participants were infected with P. malariae
and 18% with P. ovale indicates that the number of
mixed infections receiving ACTs is substantially
larger than previously thought. Mombo-Ngoma
et al. reported, in 38 Gabonese patients, a 28-day
cure rate by microscopy of 100% for AL in treatment
of P. malariae, P. ovale and mixed infections in
Gabon, although post hoc PCR revealed that only 19
of the patients in the study had been correctly
diagnosed with non-falciparum malaria (Mombo-
Ngoma et al. 2012). In contrast, Dinko et al. detected
persistent P. malariae and P. ovale spp. infections in
Ghanaian schoolchildren 21 days after ACT treat-
ment using qPCR as the endpoint measure (Dinko
et al. 2013). Therefore we strongly advocate that
further studies are needed to understand the response
of non-falciparum malaria to ACT treatment, and
these should deploy molecular parasite detection as
the primary endpoint. The development of speciﬁc
molecular diagnostic tests for ﬁeld-based detection
of P. malariae and P. ovale spp. would be of great
assistance in these endeavours.
It must be borne in mind that our study did
not formally determine how well the participants
complied with the approved antimalarial treatment
regime, i.e. two doses a day for 3 days after
consumption of fatty food (WHO, 2010a). Measure-
ment of day 7 lumefantrine levels in our participants
would have provided a means to verify adequate
dosing. Thus, poor compliance may at least partially
explain why some of the children remained para-
sitaemic after two or three doses of antimalarial
medication. It must also be noted that de-worming
drugs, praziquantel and albendazole, were co-
administered with AL. There is a paucity of
information on the putative interactions of anthel-
mintics with antimalarial drugs, and more research
on this topic is warranted, especially given the
changing landscape of mass drug administration in
sub-Saharan Africa (WHO, 2010b). There are ad-
ditional limitations to the analysis presented here.
First, due to logistical constraints, study participants
were only followed up for 17 or 24 days. It would
have been preferable to extend this period to 28 or
42 days after treatment to allow a more direct
comparison with published eﬃcacy studies. Second,
the real-time PCR analysis did not distinguish
between asexual parasites and gametocytes. Although
no gametocytes were observed by microscopy after
AL treatment (data not shown), it is possible that
sub-microscopic gametocytes were present. Third, it
is possible that the proportion of new infections on
day 7 and day 17 as determined by PCR genotyping is
overestimated. Alleles can remain undetected using
the recommended genotyping procedure particularly
if they represent low abundance clones, leading to
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misclassiﬁcation of recrudescences as new infections
(Juliano et al. 2010). However, there is also the
possibility of misclassifying new infections as recru-
descences in areas of intense transmission, as children
can be re-infected with parasites of the same genotype
as the original infection. Thus care should be
exercised when interpreting PCR ‘corrected’ results.
CONCLUSION
The burden of malaria remains high in Uganda.
Whilst the Ugandan malaria policy promotes AL as
the ﬁrst-line antimalarial treatment and is doubtless
saving many lives, other challenges in its implemen-
tation remain. Our results suggest that even though
ACTs remain highly eﬃcacious in treatment of
clinical disease in sub-Saharan Africa, asymptomatic
and submicroscopic falciparum and non-falciparum
infections often persist after treatment. These infec-
tions may be signiﬁcant in terms of later recurrence of
clinical disease and parasite transmission. Improved
diagnostics are needed for ﬁeld-based detection of
non-falciparum malaria infections, gametocytes
and drug-resistance markers. Increased community-
based surveillance using a range of diagnostic tests is
required to provide further insights into the extent
of persistent parasitaemia after ACT treatment and
for early detection of ACT-tolerant parasites in sub-
Saharan Africa. Finally, new in vivo study protocols,
with sensitive molecular endpoints, must now be
developed that are speciﬁcally designed to measure
the eﬃcacy of antimalarial regimens against asymp-
tomatic and sub-patent Plasmodium spp. infections.
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